Excelerate Health Ventures
Excelerate Health Ventures is a Durham, NC-based venture capital firm founded in 2014 that invests at seed and Series A in B2B AI-Powered Pharma Tech and tech-enabled pharma services, managing 19 portfolio companies across three funds.
- Company typePrivate
- Founded2014
- HeadquartersDurham, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Excelerate Health Ventures does
Excelerate Health Ventures (EHV) is a Durham, North Carolina-based venture capital firm founded in 2014 that invests exclusively in B2B Pharma Tech and tech-enabled pharma services at the seed and Series A stages. The firm manages a concentrated portfolio of 19 companies with 8 strategic exits to date, deploying capital-efficient investment structures and typically leading or co-leading rounds while taking board seats to drive governance and value creation. Its portfolio spans AI-enabled clinical trial matching (BEKHealth), randomization and trial supply management (Korio), prior authorization automation (Itiliti Health), vendor risk management (Censinet), medication shortage platforms (OrbitalRx), AI market intelligence (S2N Health, Qoniq), and clinical research services (Elligo Health Research, Health Decisions). Earlier funds (Fund I at $11M in 2016 and Fund II at $35M in 2021) supported a broader healthcare software mandate across providers, payers, and pharma; Fund III, whose initial closing was announced in April 2026, narrows the thesis exclusively to AI-Powered Pharma Tech.
The firm is led by three Managing Partners—B. Bobby Bahram, Maulik Mehta, and Andrew Schwab—each with 25–30 years of healthcare and Pharma Tech operating, M&A, and venture experience, and is supported by four Venture Partners and 25+ advisors drawn from pharmaceutical companies, health systems, payers, CROs, and clinical research organizations. EHV's revenue model follows standard venture fund economics: management fees on committed and deployed AUM across its three funds, plus carried interest on realized portfolio exits; the firm does not publicly disclose fee terms or LP composition. Distribution and deal sourcing are network-led rather than marketing-led, relying on a proprietary deal engine built over two decades of Pharma Tech operating experience and a strategic investor network whose LPs are pharma, provider, and payer decision-makers who simultaneously serve as portfolio company customers and acquirers—a structure designed to compress the timeline from inception to scale to exit.
Excelerate Health Ventures firmographics
Firmographics- Name
- Excelerate Health Ventures
- Legal name
- Excelerate Health Ventures
- Website
- https://exceleratehealth.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Excelerate Health Ventures is a Durham, NC-based venture capital firm founded in 2014 that invests at seed and Series A in B2B AI-Powered Pharma Tech and tech-enabled pharma services, managing 19 portfolio companies across three funds.
- Ownership category
- akta.pro rank
Excelerate Health Ventures industry classification
Industry- Product category
- Venture Capital
- NAICS
- Other Investment Pools and Funds (5259), Portfolio Management and Investment Advice (523940)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Healthcare & Life Sciences Growth Equity (FSANACAB)
- akta.pro secondary industry
- Corporate LP Programs (Corporate as LP in VC/PE funds) (FSANAHAH)
Keywords
Where Excelerate Health Ventures is headquartered
LocationHeadquarters
- HQ city
- Durham
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Excelerate Health Ventures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Others
Revenue model
- Fund Management: EHV generates returns through traditional venture capital fund economics including management fees on AUM and carried interest (performance fees) on successful portfolio exits. Fund III is currently active with AI-Powered Pharma Tech focus.
- Investment Returns: Realized returns through portfolio company exits including acquisitions by strategic acquirers (Press Ganey, Allscripts, Availity, Nanox, Premier Research, HealthStream, Falfurrias Management Partners, Wellbox) generating carried interest for the fund.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Excelerate Health Ventures product offering
Product offeringCore offering
Excelerate Health Ventures is a sector-focused venture capital firm that raises and manages funds to invest in early-stage (seed and Series A) AI-Powered Pharma Tech and tech-enabled pharma services companies. The firm provides portfolio companies with capital, operational support, and access to a strategic network of pharma, provider, and payer decision-makers who serve as customers, partners, and acquirers. The firm has deployed capital across 19 portfolio companies and achieved 8 strategic exits.
Product overview
Excelerate Health Ventures is a sector-focused venture capital fund, not a product company. The firm's core offering is Fund III, which invests exclusively in AI-Powered Pharma Tech and tech-enabled pharma services. The fund deploys capital-efficient B2B SaaS investments at seed and Series A stages, building a portfolio of 19 companies across Pharma Tech and Health Tech. The portfolio includes AI/ML-enabled platforms for clinical trial matching (BEKHealth), market intelligence (S2N Health), and healthcare intelligence (Qoniq), as well as RTSM platforms (Korio), prior authorization automation (Itiliti Health), and medication shortage management (OrbitalRx). The fund provides portfolio companies with customer access, operational support, and a healthcare-only network of strategic partners.
Differentiator
Problem solved
Functional benefit
Products and services
- Fund I Excelerate Health Ventures' first venture capital fund that raised $11 million in July 2016 to invest in digital health companies across provider, payer, and pharma markets.
- Fund II Excelerate Health Ventures' second healthcare venture capital fund launched in January 2021 at $35 million to invest in capital-efficient healthcare technology startups.
- Fund III – AI-Powered Pharma Tech & Services Excelerate Health Ventures' currently active fund focused exclusively on AI-Powered Pharma Tech and tech-enabled pharma services, targeting capital-efficient B2B SaaS and tech-enabled services companies at seed and Series A stages.
Companies that use Excelerate Health Ventures
Customer profileNamed customers11 records
Segments3 records
Ideal customer profiles2 records
Excelerate Health Ventures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Excelerate Health Ventures partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights5 records
Excelerate Health Ventures competitors and assessment
Company assessmentOthers
Direct peers
- Rock Health: Seed-stage digital health venture fund that invests in early-stage healthcare technology companies, often leading rounds and providing strategic support. Directly comparable to EHV's seed/Series A healthcare software and tech-enabled services focus, though Rock Health's thesis is broader digital health rather than pharma-specific.
- HealthX Ventures: Early-stage healthcare technology venture fund based in the Midwest investing in seed and Series A digital health companies. Comparable to EHV in stage focus, check size, and operator-led value-add approach.
- LRVHealth: Early-stage venture firm focused exclusively on healthcare, backed by a consortium of health systems and healthcare executives that act as customers and strategic partners for portfolio companies. Highly comparable to EHV's strategic LP network thesis and provider/payer decision-maker orientation.
- 7wireVentures: Early-stage digital health venture fund investing in seed and Series A companies with an operator-led model and connected consumer health network. Comparable to EHV in stage focus and the use of strategic LP networks to accelerate portfolio traction.
- Flare Capital Partners: Early-stage healthcare technology venture fund that leads seed and Series A rounds and takes board seats to support founders. Directly comparable to EHV in stage focus, lead/co-lead positioning, and active portfolio support.
- AV8 Ventures: Early-stage venture fund focused on health/care technology and tech-enabled services, leading seed and Series A rounds. Comparable to EHV in stage, sector, and lead-investor posture.
- Maverick Ventures: Early-stage venture fund investing in healthcare and technology companies at the seed stage. Comparable to EHV in stage focus and seed/Series A check sizes, with a similarly operator-led model.
Broad incumbents
- Optum Ventures: The corporate venture arm of UnitedHealth Group/Optum, investing across digital health and healthcare services with significantly larger fund sizes than EHV. Overlaps as a healthcare-focused strategic investor with customer-acquirer LP dynamics, but operates at much larger scale and broader scope than EHV's seed/Series A focus.
- General Catalyst: Large multi-stage venture firm with a dedicated healthcare practice (Health Assurance) investing from seed through growth stages. Overlaps with EHV in early-stage healthcare investing but operates at vastly greater scale, broader sector coverage, and later-stage capacity.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Excelerate Health Ventures social profiles
Digital presenceExcelerate Health Ventures financial estimates
Financial estimateRevenue estimate
Valuation estimate
Excelerate Health Ventures leadership team
Management profileNumber of profiles
Profiles3 records
Excelerate Health Ventures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Excelerate Health Ventures M&A and investment
M&A and investmentM&A
Investments30 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Excelerate Health Ventures
What does Excelerate Health Ventures do?
Excelerate Health Ventures is a sector-focused venture capital firm that raises and manages funds to invest in early-stage (seed and Series A) AI-Powered Pharma Tech and tech-enabled pharma services companies. The firm provides portfolio companies with capital, operational support, and access to a strategic network of pharma, provider, and payer decision-makers who serve as customers, partners, and acquirers. The firm has deployed capital across 19 portfolio companies and achieved 8 strategic exits.
Is Excelerate Health Ventures a public or private company?
Excelerate Health Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Excelerate Health Ventures founded?
Excelerate Health Ventures was founded in 2014. It employs 1 to 10 people.
Where is Excelerate Health Ventures based?
Excelerate Health Ventures is headquartered in Durham, United States, in the North America region.
How does Excelerate Health Ventures make money?
Two revenue lines are on record. Fund Management is the primary driver. The others are investment Returns.
Who are Excelerate Health Ventures's main competitors?
Echo Health Ventures is listed as an others. Direct peers are Rock Health, HealthX Ventures, LRVHealth, 7wireVentures, Flare Capital Partners, AV8 Ventures and Maverick Ventures. Broad incumbents are Optum Ventures and General Catalyst.
Does Excelerate Health Ventures have an API?
No public API is recorded for Excelerate Health Ventures.
What industry is Excelerate Health Ventures in?
Excelerate Health Ventures's product category is Venture Capital. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of FSANAHAH, Corporate LP Programs (Corporate as LP in VC/PE funds). Its NAICS code is 5259 and its SIC code is 6282.